David S. Hong, MD | Authors


EP. 4A: First -generation TRK Inhibitors and Treatment Resistance in NTRK Fusion-positive Cancers

April 27, 2022

In the third video interview of the series, David S. Hong, MD, from the University of Texas MD Anderson Cancer Center discusses the safety and efficacy of first-generation TRK inhibitors and reflects on challenges affecting next-generation TRK inhibitors including research into mechanisms of treatment resistance.

TRK Inhibitors for Advanced Solid Tumors: Next Steps in Research

March 25, 2021

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, shares his enthusiasm for ongoing research efforts to optimize treatment for patients with advanced solid tumors who harbor NTRK gene fusions.